KAHR Medical, the developer of novel drugs for the treatment of cancer and autoimmune diseases, will raise $2.6 million at a pre-investment valuation of $11 million. KAHR Medical is a portfolio company in which Hadasit Bio-Holdings, a publicly traded portfolio of biotech companies based on intellectual property developed by the Hadassah University Hospital, and Sanofi hold approximately 70% and 20% respectively. Thomas Eldered, co-owner of Recipharm, will invest $2 million and hold approximately 15% of the company. The pharmaceutical company Sanofi will maintain its current holdings with an investment of $500,000. Hadasit Bio-Holdings will invest an additional $100,000 and reduce its holding in the company to approximately 55%.